O	0	1	[
O	1	11	Randomized
O	12	22	controlled
O	23	28	trial
O	29	31	of
O	32	35	two
O	36	41	kinds
O	42	44	of
B-intervention	45	49	home
I-intervention	49	50	-
I-intervention	50	58	produced
I-intervention	59	68	docetaxel
O	69	71	in
B-location	72	77	China
O	78	81	for
B-eligibility	82	90	advanced
I-eligibility	91	97	breast
I-eligibility	98	104	cancer
O	104	105	]
O	105	106	.

O	107	110	Two
O	111	116	kinds
O	117	119	of
O	120	124	home
O	124	125	-
O	125	133	produced
O	134	143	docetaxel
O	144	146	in
O	147	152	China
O	152	153	,
O	154	163	injection
O	164	174	Yiyoutasai
O	175	178	and
O	179	188	injection
O	189	193	Aisu
O	193	194	,
O	195	199	have
O	200	203	the
O	204	208	same
O	209	218	structure
O	218	219	.

O	220	224	Data
O	225	229	from
O	230	241	preclinical
O	242	247	study
O	248	251	had
O	252	257	shown
O	258	262	that
O	263	272	injection
O	273	283	Yiyoutasai
O	284	287	has
O	288	291	the
O	292	296	same
O	297	313	pharmacokinetics
O	314	317	and
O	318	326	toxicity
O	327	329	as
O	330	339	injection
O	340	344	Aisu
O	344	345	.

O	346	350	This
O	351	356	study
O	357	360	was
O	361	363	to
O	364	372	evaluate
O	373	376	the
O	377	385	efficacy
O	386	389	and
O	390	398	toxicity
O	399	401	of
O	402	411	injection
O	412	422	Yiyoutasai
O	423	425	in
O	426	434	treating
O	435	443	advanced
O	444	450	breast
O	451	457	cancer
O	457	458	.

O	459	467	Eligible
O	468	474	breast
O	475	481	cancer
O	482	490	patients
O	491	495	were
O	496	504	enrolled
O	505	508	and
O	509	517	randomly
O	518	526	assigned
O	527	529	to
O	530	535	study
O	536	541	group
O	542	545	and
B-control	546	553	control
I-control	554	559	group
O	559	560	,
O	561	564	and
O	565	573	received
O	574	583	injection
O	584	586	of
O	587	589	75
O	590	592	mg
O	592	593	/
O	593	594	m
O	594	595	(
O	595	596	2
O	596	597	)
B-intervention	598	608	Yiyoutasai
O	609	611	or
B-control	612	616	Aisu
O	616	617	,
O	618	630	respectively
O	630	631	.

O	632	635	The
O	636	646	injections
O	647	651	were
O	652	660	repeated
O	661	666	every
O	667	668	3
O	669	674	weeks
O	674	675	.

O	676	679	All
O	680	688	patients
O	689	697	received
O	698	700	at
O	701	706	least
O	707	708	2
O	709	715	cycles
O	715	716	.

O	717	720	The
O	721	729	efficacy
O	730	732	of
O	733	743	Yiyoutasai
O	744	747	and
O	748	752	Aisu
O	753	757	were
O	758	767	evaluated
O	768	773	after
O	774	783	treatment
O	783	784	.

O	785	786	A
O	787	792	total
O	793	795	of
B-total-participants	796	798	67
O	799	807	patients
O	808	812	were
O	813	821	enrolled
O	821	822	:
B-intervention-participants	823	825	33
O	826	828	in
O	829	834	study
O	835	840	group
O	840	841	,
O	842	845	and
B-control-participants	846	848	34
O	849	851	in
O	852	859	control
O	860	865	group
O	865	866	.

O	867	869	Of
O	870	873	the
B-intervention-participants	874	876	31
O	877	886	evaluable
O	887	892	cases
O	893	895	in
O	896	901	study
O	902	907	group
O	907	908	,
B-iv-bin-abs	909	910	1
O	911	919	achieved
B-outcome	920	928	complete
I-outcome	929	938	remission
I-outcome	939	940	(
I-outcome	940	942	CR
I-outcome	942	943	)
O	943	944	,
B-iv-bin-abs	945	946	9
O	947	955	achieved
B-outcome	956	963	partial
I-outcome	964	973	remission
I-outcome	974	975	(
I-outcome	975	977	PR
I-outcome	977	978	)
O	978	979	,
B-iv-bin-abs	980	982	11
O	983	986	had
B-outcome	987	993	stable
I-outcome	994	1001	disease
I-outcome	1002	1003	(
I-outcome	1003	1005	SD
I-outcome	1005	1006	)
O	1006	1007	,
O	1008	1011	and
B-iv-bin-abs	1012	1014	10
O	1015	1018	had
B-outcome	1019	1030	progressive
I-outcome	1031	1038	disease
I-outcome	1039	1040	(
I-outcome	1040	1042	PD
I-outcome	1042	1043	)
O	1043	1044	;
O	1045	1048	the
B-outcome	1049	1054	total
I-outcome	1055	1063	response
I-outcome	1064	1068	rate
O	1069	1072	was
B-iv-bin-percent	1073	1075	22
I-iv-bin-percent	1075	1076	.
I-iv-bin-percent	1076	1078	22
I-iv-bin-percent	1078	1079	%
O	1079	1080	.

O	1081	1086	There
O	1087	1091	were
B-cv-bin-abs	1092	1093	1
B-outcome	1094	1096	CR
O	1096	1097	,
B-cv-bin-abs	1098	1099	5
B-outcome	1100	1102	PR
O	1102	1103	,
B-cv-bin-abs	1104	1106	19
B-outcome	1107	1109	SD
O	1109	1110	,
O	1111	1114	and
B-cv-bin-abs	1115	1116	9
B-outcome	1117	1119	PD
O	1120	1122	in
O	1123	1130	control
O	1131	1136	group
O	1136	1137	;
O	1138	1141	the
B-outcome	1142	1147	total
I-outcome	1148	1156	response
I-outcome	1157	1161	rate
O	1162	1165	was
B-cv-bin-percent	1166	1168	15
I-cv-bin-percent	1168	1169	.
I-cv-bin-percent	1169	1171	15
I-cv-bin-percent	1171	1172	%
O	1172	1173	.

O	1174	1179	There
O	1180	1183	was
O	1184	1186	no
O	1187	1198	significant
O	1199	1209	difference
O	1210	1217	between
O	1218	1221	the
O	1222	1223	2
O	1224	1230	groups
O	1231	1232	(
O	1232	1233	P
O	1233	1234	=
O	1234	1235	0
O	1235	1236	.
O	1236	1239	662
O	1239	1240	)
O	1240	1241	.

O	1242	1245	The
O	1246	1252	median
O	1253	1259	follow
O	1259	1260	-
O	1260	1262	up
O	1263	1266	was
O	1267	1269	16
O	1269	1270	.
O	1270	1271	5
O	1272	1278	months
O	1279	1280	(
O	1280	1281	8
O	1281	1282	-
O	1282	1284	28
O	1285	1291	months
O	1291	1292	)
O	1292	1293	.

O	1294	1296	In
O	1297	1302	study
O	1303	1308	group
O	1308	1309	,
O	1310	1313	the
B-outcome	1314	1320	median
I-outcome	1321	1332	progression
I-outcome	1332	1333	-
I-outcome	1333	1337	free
I-outcome	1338	1346	survival
I-outcome	1347	1351	time
O	1352	1355	was
B-iv-cont-median	1356	1357	6
I-iv-cont-median	1357	1358	.
I-iv-cont-median	1358	1359	2
I-iv-cont-median	1360	1366	months
O	1367	1368	(
O	1368	1369	2
O	1369	1370	-
O	1370	1372	12
O	1373	1379	months
O	1379	1380	)
O	1380	1381	,
O	1382	1385	the
B-outcome	1386	1387	1
I-outcome	1387	1388	-
I-outcome	1388	1392	year
I-outcome	1393	1401	survival
I-outcome	1402	1406	rate
O	1407	1410	was
B-iv-bin-percent	1411	1413	68
I-iv-bin-percent	1413	1414	.
I-iv-bin-percent	1414	1416	51
I-iv-bin-percent	1416	1417	%
O	1417	1418	,
O	1419	1422	and
O	1423	1426	the
B-outcome	1427	1428	2
I-outcome	1428	1429	-
I-outcome	1429	1433	year
I-outcome	1434	1442	survival
I-outcome	1443	1447	rate
O	1448	1451	was
B-iv-bin-percent	1452	1454	40
I-iv-bin-percent	1454	1455	.
I-iv-bin-percent	1455	1457	12
I-iv-bin-percent	1457	1458	%
O	1458	1459	;
O	1460	1462	in
O	1463	1470	control
O	1471	1476	group
O	1476	1477	,
O	1478	1481	the
B-outcome	1482	1488	median
I-outcome	1489	1500	progression
I-outcome	1500	1501	-
I-outcome	1501	1505	free
I-outcome	1506	1514	survival
I-outcome	1515	1519	time
O	1520	1523	was
B-cv-cont-median	1524	1525	7
I-cv-cont-median	1525	1526	.
I-cv-cont-median	1526	1527	1
I-cv-cont-median	1528	1534	months
O	1535	1536	(
O	1536	1537	2
O	1537	1538	.
O	1538	1539	3
O	1539	1540	-
O	1540	1542	11
O	1543	1549	months
O	1549	1550	)
O	1550	1551	,
O	1552	1555	the
B-outcome	1556	1557	1
I-outcome	1557	1558	-
I-outcome	1558	1562	year
I-outcome	1563	1571	survival
I-outcome	1572	1576	rate
O	1577	1580	was
B-cv-bin-percent	1581	1583	65
I-cv-bin-percent	1583	1584	.
I-cv-bin-percent	1584	1586	23
I-cv-bin-percent	1586	1587	%
O	1587	1588	,
O	1589	1592	and
O	1593	1596	the
B-outcome	1597	1598	2
I-outcome	1598	1599	-
I-outcome	1599	1603	year
I-outcome	1604	1612	survival
I-outcome	1613	1617	rate
O	1618	1621	was
B-cv-bin-percent	1622	1624	39
I-cv-bin-percent	1624	1625	.
I-cv-bin-percent	1625	1627	71
I-cv-bin-percent	1627	1628	%
O	1628	1629	.

O	1630	1635	There
O	1636	1639	was
O	1640	1642	no
O	1643	1654	significant
O	1655	1665	difference
O	1666	1673	between
O	1674	1677	the
O	1678	1679	2
O	1680	1686	groups
O	1687	1688	(
O	1688	1689	P
O	1689	1690	=
O	1690	1691	0
O	1691	1692	.
O	1692	1695	102
O	1695	1696	,
O	1697	1698	0
O	1698	1699	.
O	1699	1702	098
O	1702	1703	,
O	1704	1705	0
O	1705	1706	.
O	1706	1709	089
O	1709	1710	,
O	1711	1723	respectively
O	1723	1724	)
O	1724	1725	.

O	1726	1732	Common
B-outcome	1733	1740	adverse
I-outcome	1741	1747	events
O	1748	1752	were
B-outcome	1753	1769	myelosuppression
I-outcome	1769	1770	,
I-outcome	1771	1780	transient
I-outcome	1781	1793	transaminase
I-outcome	1794	1803	elevation
I-outcome	1803	1804	,
I-outcome	1805	1808	and
I-outcome	1809	1817	alopecia
O	1817	1818	.

B-iv-bin-abs	1819	1822	One
O	1823	1830	patient
O	1831	1833	in
O	1834	1839	study
O	1840	1845	group
O	1846	1854	suffered
O	1855	1859	from
B-outcome	1860	1866	severe
I-outcome	1867	1875	allergic
I-outcome	1876	1884	reaction
O	1885	1890	after
O	1891	1899	infusion
O	1899	1900	,
B-cv-bin-abs	1901	1902	1
O	1903	1905	in
O	1906	1913	control
O	1914	1919	group
O	1920	1928	suffered
O	1929	1933	from
B-outcome	1934	1939	whole
I-outcome	1940	1944	body
I-outcome	1945	1950	edema
O	1950	1951	.

O	1952	1962	Yiyoutasai
O	1963	1966	and
O	1967	1971	Aisu
O	1972	1976	have
O	1977	1984	similar
O	1985	1993	efficacy
O	1994	1996	on
O	1997	2000	and
O	2001	2009	toxicity
O	2010	2012	to
O	2013	2021	advanced
O	2022	2028	breast
O	2029	2035	cancer
O	2036	2044	patients
O	2044	2045	.
